Adma Biologics (ADMA) Equity Average (2011 - 2025)

Adma Biologics has reported Equity Average for 13 years, with the latest figure at $454.3 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average rose 56.39% year-over-year to $454.3 million; the trailing twelve-month figure through Dec 2025 stood at $454.3 million (up 56.39% YoY), and the FY2025 full-year result was $413.2 million, up 70.65% from the prior year.
• Equity Average for Q4 2025 stood at $454.3 million, up from $414.8 million in the prior quarter.
• The five-year high for Equity Average was $454.3 million in Q4 2025, with the low at $100.4 million in Q1 2021.
• Historically, Equity Average has averaged $197.5 million across 5 years, with a median of $145.3 million in 2023.
• Annual changes were most pronounced in 2024 — Equity Average slipped 2.93% — and 2025, when it soared 150.05%.
• Adma Biologics' Equity Average stood at $122.0 million in 2021, then grew by 3.45% to $126.2 million in 2022, then advanced by 13.59% to $143.3 million in 2023, then soared by 102.66% to $290.5 million in 2024, then surged by 56.39% to $454.3 million in 2025.
• The last three Equity Average figures came in at $454.3 million (Q4 2025), $414.8 million (Q3 2025), and $385.9 million (Q2 2025), per Business Quant data.